Biocardia reports completion of low dose cohort enrollment for cardiallo phase i/ii clinical trial of bcda-03 allogeneic mesenchymal stem cells to treat ischemic heart failure of reduced ejection fraction (hfref)

Focus on patients with elevated markers of heart stress and inflammation procedural enhancement using fda approved morph dna steerable guide for therapeutic delivery sunnyvale, calif., feb. 13, 2025 (globe newswire) -- biocardia, inc. [nasdaq: bcda], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today completion of enrollment and dosing in the low dose cohort in its cardiallo™ allogeneic mesenchymal cell therapy phase i/ii trial.
BCDA Ratings Summary
BCDA Quant Ranking